Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced that its wholly‑owned subsidiary, Hangzhou Jingyao Biotechnology Co., Ltd., has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for BPI‑572270 Capsules, a novel pan‑RAS “non‑degradative molecular glue” inhibitor intended for the treatment of advanced solid tumors, enabling the initiation of Phase I clinical trials in the United States.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | U.S. Food and Drug Administration (FDA) |
| Approval Type | Investigational New Drug (IND) |
| IND Number | 184065 |
| Product | BPI‑572270 Capsules (oral) |
| Indication | Advanced solid tumors (晚期实体瘤) |
| Applicant | Hangzhou Jingyao Biotechnology Co., Ltd. (wholly‑owned subsidiary of Betta Pharmaceuticals) |
| Approval Date | October 2026 |
| Next Steps | Initiation of Phase I clinical trials in the United States |
Drug Profile & Mechanism of Action
- Molecule: BPI‑572270, a novel small‑molecule new chemical entity (NCE), independently developed by Betta Pharmaceuticals with full proprietary intellectual property rights.
- Target: Pan‑RAS “non‑degradative molecular glue” — a distinct mechanism from conventional RAS degraders.
- Mechanism: BPI‑572270 induces the widely expressed chaperone protein Cyclophilin A (CYPA) to bind to activated RAS mutant proteins, triggering a conformational change that prevents RAS from interacting with downstream signaling effectors (e.g., cRAF), thereby blocking the MAPK signaling pathway responsible for tumor growth.
- Mutation Coverage: Demonstrated potent preclinical inhibition across multiple RAS mutation subtypes, including KRAS, NRAS, and HRAS variants (G12X, G13X, Q61X, among others).
- Tumor Types (Preclinical): Strong inhibitory activity observed in pancreatic cancer, non‑small cell lung cancer (NSCLC), and colorectal cancer cell lines.
- PK/Safety Profile: Favorable pharmacokinetic properties and safety profile demonstrated in preclinical studies.
- Development Strategy: Potential for monotherapy across multiple RAS‑mutant cancers, or combination therapy for broader disease control.
Clinical Development Status
- China Phase I (NMPA‑approved, January 2026): BPI‑572270 received clinical trial approval from China’s National Medical Products Administration (NMPA) in January 2026. The study is currently in the dose‑escalation and dose‑expansion phase, with progress described as on‑track.
- U.S. Phase I (FDA IND, October 2026): The newly granted FDA IND (184065) authorizes first‑in‑human studies in the United States for advanced solid tumors. Specific U.S. trial design parameters — including dose‑escalation schema, planned enrollment, and primary endpoints — have not been disclosed.
Competitive Landscape
| Parameter | Detail |
|---|---|
| Only Approved Pan‑RAS(ON) Drug Globally | Daraxonrasib (brand name: RASONQUE™), developed by Revolution Medicines |
| Daraxonrasib FDA Approval | 26 August 2026 |
| Daraxonrasib Indication | Adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multi‑agent combination therapy |
| China Availability | Not yet approved in China as of the announcement date |
BPI‑572270 differentiates mechanistically as a “non‑degradative molecular glue” — distinct from RAS degrader approaches — potentially offering a complementary therapeutic profile in the rapidly evolving pan‑RAS inhibitor space.
Market Impact & Outlook
- U.S. Market Entry: The FDA IND clearance marks a key strategic milestone for Betta Pharmaceuticals, establishing a clinical development presence in the world’s largest oncology pharmaceutical market.
- RAS Mutation Opportunity: RAS mutations are among the most prevalent oncogenic drivers across solid tumors, with particularly high incidence in pancreatic cancer (~90%), NSCLC (~25–30%), and colorectal cancer (~40–50%), representing a substantial addressable patient population.
- Dual‑Market Development: With both NMPA (China) and FDA (U.S.) clinical approvals secured, Betta is pursuing a parallel development strategy across the two largest pharmaceutical markets.
- Competitive Timing: With Revolution Medicines’ daraxonrasib only recently approved (August 2026) and not yet available in China, BPI‑572270 enters a nascent therapeutic category with significant room for differentiated mechanisms and combination strategies.
- Intellectual Property: As a self‑developed NCE with full proprietary IP, BPI‑572270 provides Betta with full global development and commercialization optionality.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, clinical development plans, and commercial expectations for BPI‑572270. Actual results may differ materially due to risks including clinical trial outcomes, dose‑finding results, regulatory review timelines, competitive developments, and the inherent uncertainties of new drug research and development. Drug development involves substantial investment, long timelines, and numerous unpredictable factors. Investors are advised to exercise caution.-Fineline Info & Tech
